Want to see TSE:LOBE full AI Analyst Report?
LOBE Stock Chart & Stats
C$0.09
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.09
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.18
Previous CloseN/A
Volume205.10K
Average Volume (3M)19.65K
Market Cap
C$21.31M
Enterprise ValueC$25.61
Total Cash (Recent Filing)C$5.21M
Total Debt (Recent Filing)C$338.40K
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,102,500
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused R&D And IP In Psychedelic TherapiesA concentrated R&D strategy and active pursuit of IP around delivery methods and compounds creates a structural differentiation versus generalist peers. Durable benefits include exclusive commercialization rights and licensing potential that can underpin partnerships and margin expansion if clinical progress and regulatory pathways advance.
Balance-sheet Stabilization To Positive EquityRestoring positive equity represents a meaningful structural improvement in solvency, reducing immediate bankruptcy risk and lengthening runway for R&D. This stabilization increases the company's ability to negotiate non-dilutive partnerships or structured financing and preserves operational optionality over coming quarters.
Relatively Small Absolute Debt BurdenLow absolute debt keeps fixed financing costs minimal and limits near-term creditor pressure, helping cash flow flexibility. Structurally, a light debt load preserves the firm's ability to pursue equity or partnership-funded development without heavy interest servicing that would otherwise erode funds available for trials or commercialization.
Bears Say
Zero Revenue Across TTMSustained zero revenue indicates the business lacks commercialized products or recurring sales, forcing continued reliance on financing to fund operations. Over months this undermines self-funding prospects, increases execution risk for R&D commercialization, and makes long-term viability contingent on successful product launches or external capital.
Persistent Negative Operating And Free Cash FlowMaterial negative operating and free cash flow steadily depletes liquidity and shortens runway absent new financing. Structurally, ongoing cash burn raises the likelihood of dilutive capital raises, constrains investment in trials or commercialization, and increases execution risk over the next several quarters.
Worsening Losses And Volatile Capital BaseLarge and worsening operating losses combined with volatile returns on equity signal weak earnings quality and erosion of the capital base. Structurally, this reduces ability to attract strategic partners or favorable financing, increases governance and execution scrutiny, and heightens dilution risk for stakeholders.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.03 and its highest was C$0.18 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$21.31M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Dec 18, 2026 which is in 137 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Jul 30, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―